Fisetin is the plant flavonoid with a second act. For years it was a quiet neuroprotective molecule studied mainly by Pamela Maher's lab at the Salk Institute. Then a 2018 screen out of James Kirkland and Tamar Tchkonia's group at the Mayo Clinic identified it as one of the most potent natural fisetin senolytic compounds tested — a small molecule that preferentially kills senescent cells and extended healthspan in mice. That discovery pushed fisetin into longevity clinics, supplement stacks, and several active human trials. This article walks through what is real, what is hopeful, and what is still unknown.
What Is Fisetin?
Fisetin (3,3',4',7-tetrahydroxyflavone) is a flavonol, a subclass of flavonoids, found in strawberries (the densest dietary source), apples, persimmons, onions, cucumbers, and grapes. Strawberries carry roughly 160 micrograms per gram, meaning a cup supplies around 25 mg. Most other foods deliver far less.
Like many flavonoids, fisetin has modest bioavailability when consumed orally. It is rapidly metabolized, poorly absorbed in its free form, and cleared quickly. This pharmacokinetic profile is a major part of why the senolytic research community has explored intermittent high-dose protocols — the goal is to briefly flood tissues with the compound rather than maintain steady-state levels.
The Science: Why It Kills Senescent Cells
Cellular senescence is a state in which cells permanently exit the cell cycle but remain metabolically active, secreting inflammatory factors known as the senescence-associated secretory phenotype (SASP). These cells accumulate with age and are now widely accepted as drivers of age-related tissue dysfunction. Senolytics are drugs that selectively kill senescent cells, ideally sparing healthy ones.
The Kirkland-Tchkonia framework — laid out in their 2015 Aging Cell paper with Yi Zhu — proposes that senescent cells depend on specific pro-survival networks (SCAPs, senescent cell anti-apoptotic pathways) that can be targeted. The first senolytic combination they validated was dasatinib plus quercetin (D+Q). Fisetin emerged later as a structurally related flavonoid with apparently stronger single-agent senolytic activity.
Mechanistically, fisetin appears to disrupt multiple SCAP nodes: it inhibits PI3K/AKT signaling, modulates BCL-2 family proteins, and has direct effects on mitochondrial function in senescent cells. It is also a pan-antioxidant, which complicates interpretation — some of its effects in early studies may not be senolysis per se.
Pamela Maher's earlier work (2017 and before) characterized fisetin as a neuroprotective compound that enhances glutathione synthesis, activates Nrf2, and protects neurons from oxidative damage in cell and mouse models of neurodegeneration. That line of research is distinct from but complementary to the senolytic framing.
The Evidence
The 2018 senolytic screen
Yousefzadeh, Kirkland and colleagues published the pivotal paper in EBioMedicine in 2018, "Fisetin is a senotherapeutic that extends health and lifespan." They screened a panel of flavonoids against senescent cells and found fisetin to be the most potent. In aged mice, late-life intermittent administration (9 cycles) reduced senescent cell markers in multiple tissues, reduced SASP, and extended median and maximum lifespan.
The paper became a touchstone for the senolytic field because it showed a natural molecule — not a repurposed cancer drug like dasatinib — producing meaningful benefits in old mice.
Mayo Clinic human trials
The Mayo Clinic has run and is running multiple fisetin trials. The AFFIRM-LITE Phase 2 trial in frailty (elderly women) tested intermittent high-dose oral fisetin at 20 mg/kg for two consecutive days. Additional trials have explored fisetin in COVID-19-related inflammation (on the theory that SARS-CoV-2 triggers senescence), bone loss, osteoarthritis, chronic kidney disease, and skeletal muscle dysfunction.
As of early 2026, the clinical data is still preliminary. Some trials have reported reductions in circulating SASP markers and modest improvements in physical function; others have been negative or inconclusive. No trial has yet shown the dramatic effects that the mouse data suggested.
This is consistent with a recurring pattern in the senolytic field: mouse data is striking, human translation is modest, and better-designed trials are ongoing. The senolytics 2026 trial results article on D+Q covers the parallel trajectory of the other leading senolytic.
Current Interventions: What People Are Actually Doing
The high-dose intermittent protocol. The most common biohacker approach is derived from the Mayo trials: roughly 20 mg/kg of oral fisetin for two consecutive days, taken once a month or once a quarter. For a 70 kg adult, that is about 1,400 mg per day for two days. Most people take it with a fatty meal or a lipid carrier to improve absorption.
Liposomal and novel formulations. Because bioavailability is poor, several brands (Doseology, Neurohacker, and others) sell liposomal fisetin or fisetin combined with phytosomes, black pepper extract, or cyclodextrin complexes. In vitro data suggests these can improve absorption several-fold, but head-to-head human pharmacokinetic studies are sparse.
Dietary. Strawberries supply meaningful fisetin, but getting to "senolytic doses" from food is not realistic. A cup of strawberries delivers roughly 25 mg; the mouse-equivalent senolytic dose would require orders of magnitude more.
Comparison with dasatinib plus quercetin. D+Q is the more-studied combination in the clinic, with more peer-reviewed trial reports but also a prescription-only component (dasatinib). Fisetin's attraction is that it is an over-the-counter supplement, which is also its risk: unregulated, inconsistent quality, and no medical supervision.
Connection to Gene Editing and Peptides
Senolytics, including fisetin, target the downstream consequence of cellular senescence. Gene-editing approaches attack the problem at different points. CAR-T cells targeting urokinase plasminogen activator receptor (uPAR) — a surface marker enriched on senescent cells — have been shown by Scott Lowe's group at Memorial Sloan Kettering to clear senescent cells in mouse models. Engineered T cells that recognize senescence-associated antigens are an active area of preclinical development.
On the peptide side, FOXO4-DRI — a short peptide that disrupts the FOXO4-p53 interaction that keeps senescent cells alive — was the first peptide senolytic, developed by Peter de Keizer's group in the Netherlands. It remains experimental and has not entered formal clinical trials, but it helped prove the principle that senescent cells could be selectively targeted with biologics as well as small molecules.
Fisetin sits alongside these as an accessible, small-molecule entry point into the same therapeutic category. The choice is really about how much evidence and supervision you demand.
Limitations and Open Questions
Human evidence is still thin. The mouse data is good; the human data is early. Biohackers taking 20 mg/kg monthly are extrapolating from small trials that have not yet produced hard outcome data.
Bioavailability. Oral fisetin absorption is poor. A 1,400 mg oral dose does not produce plasma concentrations close to what in vitro senolytic activity requires. Either the effective mechanism is local (gut, liver), metabolites are the active species, or brief peak exposures matter more than steady state. The PK-PD picture is genuinely unresolved.
Is it actually senolytic in humans? Mouse senescent cell assays are well-validated. Human tissue senescence markers in trial participants have been more equivocal. Until we see clean, reproducible reductions in senescent cell burden with accompanying functional benefits, "fisetin is senolytic in humans" remains an extrapolation.
Quality and consistency. Over-the-counter fisetin varies widely in purity, polymorph, and delivery vehicle. There is no standardization of "clinical-grade" fisetin outside research contexts.
Frequency and dose unknowns. How often to cycle, whether two days is enough, and whether long-term intermittent exposure is safe are all open questions.
FAQ
How much fisetin should I take and how often?
The Mayo trial protocol is 20 mg/kg per day for two consecutive days, repeated intermittently. For a 70 kg adult, that is about 1,400 mg daily for two days. Whether monthly, quarterly, or annually is optimal is unknown.
Is fisetin better than quercetin?
In the Kirkland 2018 screen, fisetin was more potent than quercetin as a single-agent senolytic in the assays used. In humans, no head-to-head trial has confirmed this. Quercetin is usually used as part of the dasatinib + quercetin combination rather than alone.
Can I just eat strawberries instead?
You will get health benefits from eating strawberries, but you will not reach the doses used in the Mayo trials from food alone. Diet is not a substitute for a senolytic protocol, if a senolytic protocol is even the right framing.
Is fisetin safe?
Short-term high-dose trials have not reported serious adverse effects. Long-term safety and off-target effects have not been comprehensively studied. People on anticoagulants or with active cancer should discuss with a physician.
Does liposomal fisetin actually absorb better?
In vitro and preclinical data suggest yes, sometimes substantially. Robust human pharmacokinetic comparisons are limited, and product quality varies.
How does fisetin compare to dasatinib + quercetin?
D+Q has more clinical trial data and is typically used in supervised settings because dasatinib is prescription-only. Fisetin is over-the-counter, easier to access, and has a cleaner safety profile, but weaker human outcome data so far.
